SAN DIEGO–(BUSINESS WIRE)–Cytonus Therapeutics Inc., a biotechnology company developing new
platforms for delivering biologics, announced today that it will be
presenting preclinical data for its Cargocyte™ technology platform at
the American Society of Gene and Cell Therapy (ASGCT) annual meeting
April 29 – May 2 in Washington, DC.
“We are excited to be presenting our preclinical data supporting
Cargocytes™, a first-of-its-kind, cell-based platform technology for
delivery of an Oncolytic Virus into metastatic tumors,” said Remo
Moomiaie-Qajar, M.D., president and CEO of Cytonus. “Our technology
unleashes the promise of using Oncolytic Viruses to treat solid tumors
by addressing a number of critical problems they inherently have, mainly
homing the viruses to specific tissue without the immune system
destroying it and then delivering those viruses into tumor cells. In
addition, we are proud of our growing immune-oncology work with our
Cargocytes and look forward to sharing our data at this year’s ASGCT
Cargocytes are engineered allogenic cell lines that can carry a variety
of payloads like small molecule compounds, gene editing therapies,
therapeutic RNAs, and powerful biologics such as immune modulating
cytokines, antibodies and oncolytic viruses.
Details of the presentations:
Abstract Title: Cargocyte™ Biofactories: A New Versatile Cell
Therapy Platform for Delivery of a Wide Range of Biologics
Session Date/Time: Monday Apr 29, 2019 5:00 PM – 6:00 PM
title: Cancer-Targeted Gene & Cell Therapy
Final abstract number: 272
Abstract Title: Cargocyte™ Biofactories: A Novel Platform
for Delivering Oncolytic Viruses to Treat Metastatic Cancer
Session Date/Time: Tuesday Apr 30, 2019 3:30 PM – 5:15 PM
title: Oncolytic Viruses II
Our Presentation Time: 4:00 PM – 4:15 PM
abstract number: 404
Abstract Title: Cargocytes™: A Novel Cell Therapy
Platform to Drive Anti-Tumor Immunity
Session Date/Time: Tuesday Apr 30, 2019 5:00 PM – 6:00 PM
title: Cancer-Immunotherapy, Cancer Vaccines
Final abstract number: 578
Cytonus will also be presenting at the Bio International Convention,
June 3-6, 2019 in Philadelphia.
Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a biopharmaceutical company developing a
next-generation Adoptive Cellular Transport platform called Cargocytes™.
The San Diego-based company’s proprietary Cargocyte™ platform are
cellular-engineered transporters of a multiplicity of therapeutic
payloads to tissue in a selective, controllable and potent off-the-shelf
cellular therapy for the potential treatment of several diseases across
multiple therapeutic areas. Cytonus’ initial focus is to advance
Cargocyte™ candidates for the treatment of rare and difficult to treat
cancers and inflammatory diseases. For more information, visit www.cytonus.com
or follow us on LinkedIn.
Statements in this news release, which relate to other than strictly
historical facts, such as statements about Cytonus’ plans and
strategies, new and existing products and technologies, anticipated
clinical and regulatory pathways, and markets for its products are
forward-looking statements. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify forward-looking
statements that speak only as of the date hereof. Such statements
involve risks and uncertainties that could cause actual results to
differ materially from anticipated results due to many factors,
including regulatory and development risks. Cytonus undertakes no
obligation to publicly update or revise any forward-looking statements.
This news release is neither an offer to sell, nor the solicitation of
any offer to purchase, any security.